EFFICACY OF MAGNESIUM SULFATE IN THE TREATMENT OF NEONATAL HYPOXIC ISCHEMIC ENCEPHALOPATHY

Objective To evaluate the effects of magnesium sulfate on neonatal hypoxic ischemic encephalopathy (HIE). Methods 76 patients with neonatal HIE were randomly divided into two groups. Control group: 38 cases were treated with general therapy only. Treatment group: 38 cases were treated with general therapy and 250g/L magnesium sulfate 0.1mL/kg intravenous drip. Results The period of relieving the clinical symptoms in the treatment group was significantly shorter than that of the control group (3.8±1.3) days vs (6.2±1.7) days ( t=6.67, P 0.01). After 10 days of treatment, the recovery rate of brain CT in the treatment group was significantly higher than that of the control group (47.2% vs 22.8%, χ 2=4.62, P 0.05). The activity of serum creatine phosphokinase BB between the treatment group and the control group was significantly different( 6.21 ± 1.83 )U/L vs (11.26±2.14)U/L ( t=10.74, P 0.01). The concentration of serum magnesium and calcium was statistically different between the treatment group and the control group (2.16±0.24)mmol/L vs (1.82±0.21)mmol/L, (0.91±0.13)mmol/L vs (0.68±0.12)mmol/L ( t= 6.42 , 7.72, P 0.01). No side effects were found in the treatment group. Conclusion A small dose of magnesium sulfate is safe and effective medicine for neonates with HIE. [